Get Reimbursed for Administration of Injection (CPT 96372)

CPT code 96372 is used to report the administration of a therapeutic, prophylactic, or diagnostic injection delivered by the subcutaneous (sub-Q), intramuscular (IM), or intra-arterial (IA) route. Providers can receive reimbursement for CPT 96372 when the injection is medically necessary, properly documented, and billed in accordance with payer-specific guidelines.

Understanding when to report CPT 96372, how it differs from other injection and infusion codes, and which documentation and modifier requirements apply is essential for reducing claim denials and maximizing reimbursement.

Basics of CPT 96372

The primary intent of an injection as described by 96372 is generally to deliver a small volume of medication in a single shot. The substance is given directly by subcutaneous (sub-Q), intramuscular (IM), or intra-arterial (IA) routes, as opposed to an intravenous (IV) injection/push that requires a commitment of time. 96372 CPT code reimbursement is allowed when the injection is performed alone or in conjunction with other procedures/services as allowed by NCCI.

Separate reimbursement will not be allowed for CPT code 96372 when billed in conjunction with an Evaluation and Management (E/M) Service (CPT code 99201-99499) by the same rendering provider on the same date of service. If a patient supplied medication is being administered, the same of the medication along with the dosage must be entered on the CMS-1500 Box 19 or the equivalent loop and segment of the 837P. 

Reimbursement Guidelines for CPT 96372

Across the country, in offices and facilities, coders are having trouble with CPT® 96372 Therapeutic, prophylactic, or diagnostic injection, specify substance, or drug; subcutaneous or intramuscular. As this code is applied incorrectly, providers are not being paid for this injection administration code. 

• CPT codes 96372-96379 are not intended to be reported by the physician in the facility setting. Thus, when an E/M service and a therapeutic and diagnostic Injection service are submitted with CMS Place of Service (POS) codes 19, 21, 22, 23, 24, 26, 51, 52, and 61 for the same patient by the Same Individual Physician or Other Qualified Health Care Professional on the same date of service, only the E/M service will be reimbursed and the therapeutic and diagnostic Injection(s) is not separately reimbursed, regardless of whether a modifier is reported with the Injection(s). 
• E/M services provided in a non-facility setting are considered an inherent component for providing an Injection service. If a significant, separately identifiable EM service is performed unrelated to the physician work (Injection preparation and disposal, patient assessment, provision of consent, safety oversight, supervision of staff, etc.) required for the Injection service, Modifier 25 may be reported for the EM service in addition to 96372-96379. 
• E/M service code 99211 will not be reimbursed when submitted with a diagnostic or therapeutic Injection code, with or without Modifier 25. This very low service level code does not meet the requirement for ‘significant’ as defined by CPT, and therefore should not be submitted in addition to the procedure code for the Injection.
• The Preventive Medicine codes (99381-99412, 99429) do not need Modifier 25 to indicate a significant, separately identifiable service when reported in addition to the diagnostic and therapeutic Injection service. The Preventive Medicine codes include routine services such as the ordering of immunizations or diagnostic procedures. The performance of these services is to be reported in addition to the Preventive Medicine E/M code. Therefore, diagnostic and therapeutic Injections can be reported at the same time as a Preventive Medicine code without appending Modifier 25.
• When an E/M service and an Injection or Infusion service are submitted for the same enrollee on the same date of service, there is a presumption that the E/M service is part of the procedure unless the physician identifies the E/M service as a separately identifiable service.
• You will separately reimburse the same physician for both an Injection procedure and E/M service on the same date of service if each is performed in a different place of service (POS) and the Injection was provided in a POS other than 19, 21, 22, 23, 24, 26, 51, 52, and 61. For example, if the patient only receives an Injection at a physician's office (POS 11) and later that day the patient is admitted to the hospital (POS 21), both services, the Injection service performed at the physician's office and the E/M performed later that day at the hospital, would be separately reimbursed. 
• When an E/M service and a procedure are submitted for the same enrollee on the same date of service, there is a presumption that the E/M service is part of the procedure unless the physician identifies the E/M service as a separately identifiable service. Since the Injection procedure does not include the components of a Preventive Medicine E/M service, the Injection can be reported separately and the Preventive Medicine E/M code does not need a modifier to indicate it is distinct or separate from the Injection procedure.

Billing and coding tasks can be quite demanding, it may not make much economic and strategic sense to run these operations in-house. In addition, the industry is changing at an unprecedented rate, making it difficult for medical practices to keep up with the ever-changing rules and regulations in medical billing and coding. 

Top Reasons CPT 96372 Gets Denied — And How to Prevent Them

Despite being one of the most frequently billed injection administration codes, CPT 96372 carries an unusually high denial rate — and the reasons are almost always avoidable. Understanding the most common denial triggers before you submit is the single most effective strategy to protect your revenue on this code.

The leading cause of denial is missing or incomplete drug documentation. Payers require that the specific substance administered, along with the dosage and route of administration, be clearly identified on every claim. When this information is absent from Box 19 of the CMS-1500 or the 837P equivalent, the claim will be denied as incomplete. Always document the drug name (including NDC number where required), the dose administered, and whether the route was subcutaneous, intramuscular, or intra-arterial.

The second most common denial stems from billing 96372 alongside an E/M service without the correct application of Modifier 25. When the same provider performs both an evaluation and management service and administers an injection on the same date, the E/M must be appended with Modifier 25 to signal it was a significant, separately identifiable service. Without it, payers will automatically bundle the E/M into the injection and deny one of the two charges. Critically, this rule does not apply to Preventive Medicine E/M codes (99381–99412), which can be billed alongside 96372 without Modifier 25.

A third frequent error is billing 96372 in a facility setting (Place of Service codes 19, 21, 22, 23, 24, 26, 51, 52, and 61). In these environments, the injection administration is considered part of the facility's overhead, and the physician's separate claim for 96372 will not be reimbursed. Only submit 96372 as a physician service when the injection is performed in a non-facility setting such as a physician office (POS 11) or clinic. Confirming the POS before claim submission eliminates this category of denial entirely.

Finally, unbundling violations trigger automated edits when 96372 is submitted alongside codes that include the injection administration in their work value. Always run claims through NCCI edit checks prior to submission, and ensure that the drug supply code (typically a J-code) is billed separately from the administration code — they are not interchangeable and must each appear on the claim independently.

CPT 96372 vs. CPT 96374: Knowing Which Code to Bill

One of the most consequential coding decisions in injection billing is choosing between CPT 96372 and CPT 96374 — and the difference is not merely clinical, it is financial. Selecting the wrong code means either an outright denial or, worse, a compliance risk from upcoding.

CPT 96372 covers therapeutic, prophylactic, or diagnostic injections delivered via subcutaneous (sub-Q), intramuscular (IM), or intra-arterial (IA) routes. The defining characteristic of this code is that the medication is delivered in a single, relatively small-volume injection that does not require physician time monitoring. Common examples include a B12 injection, a testosterone injection, or an allergen immunotherapy dose.

CPT 96374, by contrast, covers intravenous (IV) push administration — where the substance is delivered directly into a vein, typically by a syringe, and the administering provider must be present during the entire infusion. The IV push method is used when rapid systemic absorption is required and involves a meaningfully different clinical workflow than a standard sub-Q or IM injection.

The NCCI (National Correct Coding Initiative) edits establish clear bundling relationships between these two codes. CPT 96372 and CPT 96374 should never be billed for the same substance on the same encounter unless distinct drugs were administered by different routes during the same visit and both are separately documented. Attempting to bill both for a single drug administration event is a bundling violation subject to claim denial and, upon audit, potential overpayment recovery.

From a reimbursement standpoint, CPT 96374 typically carries a higher relative value unit (RVU) than CPT 96372, reflecting the additional clinical oversight required. This makes upcoding from 96372 to 96374 a frequent audit target. Coders must rely entirely on the documented route of administration — not the relative payment rate — to select the appropriate code.

A practical tip: if the physician's note describes the injection as "given in the deltoid," "administered in the gluteal muscle," or "injected subcutaneously in the abdomen," that is CPT 96372. If the note describes IV access, a syringe push through a catheter, or intravenous delivery, that is CPT 96374. Never assign these codes based on assumption — the route must be explicitly documented.

Payer-Specific Modifier Rules for CPT 96372: Medicare, Medicaid, and Commercial Payers

Modifier usage for CPT 96372 is not uniform across payers, and applying a one-size-fits-all approach is one of the fastest ways to generate unnecessary denials. Billing teams must maintain payer-specific modifier matrices, especially for the modifiers most commonly associated with this code: Modifier 25, Modifier 59, and Modifier JW/JZ.

• Medicare: For Medicare claims, Modifier 25 is required whenever a separately identifiable E/M service is billed on the same date as CPT 96372. Medicare's NCCI guidelines are strict — without this modifier, the E/M will be bundled into the injection and denied. Additionally, Medicare requires that wasted drug be reported using Modifier JW (drug amount discarded/not administered) when a single-dose vial or single-use package is only partially used. Failure to append Modifier JW where applicable can be flagged during RAC audits as potential overcoding of the drug supply J-code. Note: As of January 2023, Modifier JZ was introduced to attest that there was zero drug wastage, and at least one of these modifiers (JW or JZ) is now required on all applicable Medicare drug claims.
• Medicaid: Medicaid policies vary significantly by state, but a common requirement across many state programs is prior authorization for the drug being injected, even if the administration code itself (96372) does not require it. Billing the administration code without confirming the drug authorization is in place will result in a medical necessity denial. Some state Medicaid programs also require the drug's NDC (National Drug Code) on the claim for 96372 to be processed, even though this is technically associated with the J-code rather than the administration code.
• Commercial Payers: Commercial payers generally follow CPT and CMS guidance but often layer on additional requirements. Many commercial plans require Modifier 59 (distinct procedural service) when 96372 is billed alongside other procedure codes on the same date, particularly if the injection is being performed at the same anatomical site as a concurrent service. Some United Healthcare and Aetna policies, for example, apply NCCI-like bundling edits that go beyond standard CMS edits and require Modifier 59 to bypass the edit rather than Modifier 25. Always verify payer-specific LCD (Local Coverage Determination) or billing policies before assuming a modifier is or is not required.

A best practice across all payers: maintain a modifier decision tree specific to CPT 96372 within your billing software workflow. The tree should prompt billers to confirm the place of service, identify whether an E/M was performed, flag whether the drug was from a single-dose or multi-dose vial, and verify whether a concurrent procedure was performed — all before claim submission. This proactive modifier review eliminates the most frequent and most preventable sources of 96372 denial.

Medical Billers and Coders (MBC) provides medical billing and coding services that ensure on-time and accurate billing. We understand the importance of entering the right information so there are no delays or denials on behalf of the insurance provider.

To know more about our billing services, you can contact us at 888-357-3226/ info@medicalbillersandcoders.com

Reference: Injection and Infusion Services Policy, Professional